Propranolol absorption in peptic ulcer disease.
This study was designed to determine whether gastroduodenal ulcer influences propranolol absorption. Eleven patients with peptic ulcer disease and eight healthy subjects received 80 mg of propranolol orally. Serum propranolol levels were measured with high-performance liquid chromatography. Ulcer patients showed a significant decrease in mean peak concentration of propranolol (90 +/- 12 ng/ml versus 151 +/- 23 ng/ml) (p < 0.025), in the absorption constant (1.43 +/- 0.21 h-1 versus 0.96 +/- 0.12 h-1) (p < 0.05), and in the area under concentration-time curve (802 +/- 129 ng/ml.h versus 492 +/- 73 ng/ml.h) (p < 0.05). No significant difference was seen in drug effect on the heart at 90 min. We conclude that propranolol is absorbed more slowly in ulcer patients than in healthy subjects, but this delay has no clinical effect after a single dose.
Valdivieso
A
A
Dept. of Surgery, Galdakano Hospital, Vizcaya, Spain.
Calvo
R
R
Suarez
E
E
Gonzalez
J P
JP
D000328:Adult; D005260:Female; D005753:Gastric Mucosa / Q000378:metabolism; D006801:Humans; D007408:Intestinal Absorption; D008297:Male; D008875:Middle Aged; D010437:Peptic Ulcer / Q000378:metabolism*; D011433:Propranolol / Q000493:pharmacokinetics*; D012907:Smoking
D011433:Propranolol